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BONE marrow augmentation in renal transplant recip-ients has been performed in a small number of 
centers, in an attempt to augment chimerism and/or provide 
donor-specific immunomodulatiQn. I- 14 In this report, we 
present our experience with bone marrow augmentation in 
renal transplantation over the past 7 years. 
PATIENT AND METHODS 
Between December l4, 1992, and January 1, 2000, 124 kidneylbone 
marrow transplants were performed. There were 51 (41%) cadav-
eric kidney, 59 (48%) kidney/pancreas, 8 (6%) kidney/islet, and 6 
(5%) living-related kidney recipients. The mean recipient age was 
40.4 :!: 10.5 years. The dosage of unmodified bone marrow was 3 to 
5 x 10" cells/kg, given either as a single infusion (n = 86; 69%), or 
as multiple infusions (n = 38,31%).'5 The mean donor age was 
33.0 :':: 15.5 years, and the mean cold ischemia time was 17.8 ::': 9.6 
hours. The mean number of HLA matches and mismatches was 
1.9 ::': 1.3 and 3.8 ;!: 1.3, respectively. Eighty patients who could 
have undergone kidneylbone marrow transplantation but did not 
because of lack of bone marrow availability were studied as 
controls. There were 45 (56%) cadaveric kidney, 32 (40%) kidney! 
pancreas, 2 (3%) kidney/islet, and 1 (1%) living-related kidney 
recipients in the control group. This was not a randomized trial; the 
availability of donor bone marrow was sporadic, and the total case 
material accounted for only about 10% of the transplants per-
formed during this time period. The mean recipient age was 43.8 ::': 
10.8 years. The mean donor age was 36.7 ::': 17.3 years, and the 
mean cold ischemia time was 21.9 ::': 10.0 hours. The mean number 
of HLA matches and mismatches was 2.2 ::': 1.5 and 3.5 ::': 1.6, 
respectively. 
Immunosuppression was with tacrolimus-based immunosuppres-
sion, as previously described 6 . 16 Antibody induction was not given, 
nor was radiation or cytoreduction therapy. 
The bone marrow and control protocols were submitted to and 
approved by the fnstitutiona~ Review Board of the University of 
Pittsburgh. 
RESULTS 
The mean follow up was 36.4 :':: 23.2 months. In the K/BM 
group, the 1- and 5-year actuarial patient survival was 98% 
and 85%, and the 1- and 5-year actuarial graft survival was 
97% and 76%. In the control group, the 1- and 5-year 
actuarial patient survival was 97% and 85%, and the 1- and 
5-year actuarial graft survival was 93% arid 71 % (P = NS). 
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The mean serum creatinine in the K/BM group was 1.6 ::':: 
.6 mgidL; in the control group, it was 1.6 ::':: 1.0 mgidL. 
The incidences of rejection and steroid-resistant rejec-
tion in the K/BM group were 60% and 6%; in the control 
group, they were 69% and 10%, respectively. An analysis of 
the incidence of chronic allograft nephropathy suggested a 
relative risk of .71 in the K/BM group relative to the control 
group, with a 95% confidence interval of 0.46 to 1.09. 
Although this difference did not achieve statistical signifi-
cance, it appeared to be progressive over time. 
The incidence .of symptomatic cytomegalovirus was 17% 
in the K/BM group and 18% in the control group. The 
incidence of posttransplant lymphoproliferative disorders 
(PTLD) was 3% in the bone marrow group and 0% in the 
control group (P = NS). The initial and final incidences of 
posttransplant diabetes mellitus were 21 % and 11 % in the 
bone marrow group, and 22% and 11% in the control 
group. 
Of patients who had kept their renal allografts for 1 year 
or more, 65% of K/BM patients and 61 % of the control 
patients were withdrawn from steroids. 
Chimerism, by PCR, was seen in 92% of the K/BM group 
and 64% of the.control group. The incidence of decreal>ing 
donor-specific reactivity was 45% in the K/BM group, and 
32% in the control group. Graft-versus-host disease was not 
seen in any patient. 
DISCUSSION 
This analysis confirms earlier reports suggesting that bone 
marrow augmentation in renal transplant recipients is as-
sociated with reasonable patient and graft survival,5.6.7.9.lo 
and extends these findings, with 5-year actuaria) patient and 
graft survival rates of 85% and 76%, respectively. As in 
previous analyses, no significant improvement was noted i.n 
graft survival, when compared with control patients not 
receiving bone marrow.6 •7,10 However, there is a suggestion 
that bone marrow augmentation had some immunomodu-
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latory effect, with a trend toward a progressive decrease in 
the incidence of chronic allograft nephropathy. This obser-
vation has also been made by the Miami group.8,II-J3 Also 
.noted was a slight increase in the incidence of PTLD. 
Although not statistically significant, this observation is still 
worrisome and suggests that it may be necessary to main-
tain bone marrow augmented renal transplant recipients on 
somewhat lower levels of chronic immunosuppression. 
In our report on the effect of bone marrow augmentation 
- in the simultaneous pancreas/kidney patients, there ap-
peared to be a more significant effect of bone marrow on 
reducing pancreatic graft loss to rejection. 17 Perhaps this is 
related in some way to the possible additional effect of 
transplantation of mesenteric and periduodenal lymph 
nodes and other lymphatic tissues in the p'!ncreas-duodenal 
transp Ian t. 
Important questions that remain include the impact of 
chimerism itself on patient and graft survival, and the 
impact of multiple bone marrow infusions compared to a 
single infusion. These analyses remain ongoing. 
In conclusion, bone marrow augmentation appears to be 
associated with reasonable patient and graft survival, rou-
tine augmentation of chimerism, some increase in the 
percentage of patients with decreasing donor-specific reac-
tivity, and a trend toward less chronic allograft nephropa-
thy. 
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